Substance / Medication

Zalcitabine

Overview

Active Ingredient
zalcitabine
RxNorm CUI
3363

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J, Foulkes M, Peto R et al. · Cochrane Database Syst Rev · 2000
PMID: 10908523Meta-Analysis
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J, Foulkes M, Peto R et al. · Cochrane Database Syst Rev · 2000
PMID: 10796851Meta-AnalysisFull text (PMC)
Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters.
Gerber Minja, Breytenbach Jaco C, du Plessis Jeanetta · Int J Pharm · 2008
PMID: 18006257Observational
Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Sangkitporn Somchai, Shide Luo, Klinbuayaem Virat et al. · Southeast Asian J Trop Med Public Health · 2005
PMID: 16124442Observational
Association between zalcitabine therapy for human immunodeficiency virus and granuloma annulare?
Peñas P F, Jones-Caballero M, García-Díez A · Arch Dermatol · 2001
PMID: 11453824Case Report
Zalcitabine induces ferroptosis in multiple myeloma through the TFAM-cGAS-STING-SLC7A11 axis.
Hui Juan, Jia Jiao, Feng Juan et al. · J Transl Med · 2026
PMID: 41593656Other
Vibrational and thermal analyses of multicomponent crystal forms of the anti-HIV drugs lamivudine and zalcitabine.
Martins Felipe T, Guimarães Freddy Fernandes, Honorato Sara B et al. · J Pharm Biomed Anal · 2015
PMID: 25808817Other
Identification of Novel Regulators of Zalcitabine-Induced Neuropathic Pain.
Martínez Antón L, Brea José, Domínguez Eduardo et al. · ACS Chem Neurosci · 2021
PMID: 34184863Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Zalcitabine (substance)
SNOMED CT
387187000
UMLS CUI
C0012132
RxNorm CUI
3363

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.